Pharmacoeconomics, 1170-7690

Journal

View graph of relations

Related Publications
  1. Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Witlox, W. J. A., van Asselt, A. D. I., Wolff, R., Armstrong, N., Worthy, G., Chalker, A., Buksnys, T., Stirk, L., Kleijnen, J., Joore, M. A. & Grimm, S. E., 9-Dec-2019, In : Pharmacoeconomics. 8 p.

    Research output: Contribution to journalReview articleAcademicpeer-review

  2. The burden of asthma and chronic obstructive pulmonary disease: Data from the Netherlands

    Rutten Van-Mölken, M. P. M. H. & Feenstra, T. L., 2-Jan-2001, In : Pharmacoeconomics. 19, SUPPL. 2, p. 1-6 6 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood

    Kent, S., Becker, F., Feenstra, T., Tran-Duy, A., Schlackow, I., Tew, M., Zhang, P., Ye, W., Lizheng, S., Herman, W., McEwan, P., Schramm, W., Gray, A., Leal, J., Lamotte, M., Willis, M., Palmer, A. J. & Clarke, P., Nov-2019, In : Pharmacoeconomics. 37, 11, p. 1305-1312 8 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies

    Makady, A., van Veelen, A., Jonsson, P., Moseley, O., D'Andon, A., de Boer, A., Hillege, H., Klungel, O. & Goettsch, W., Mar-2018, In : Pharmacoeconomics. 36, 3, p. 359-368 10 p.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (60) »

ID: 729269